ラザベミド
|
- ￥15900 - ￥45800
- 化學(xué)名: ラザベミド
- 英語名: LAZABEMIDE
- 別名:N-(2-アミノエチル)-5-クロロ-2-ピリジンカルボアミド;ラザベミド;ラザベミド 水和物;N-(2-アミノエチル)-5-クロロピリジン-2-カルボキサミド
- CAS番號: 103878-84-8
- 分子式: C8H10ClN3O
- 分子量: 199.64
- EINECS:
- MDL Number:MFCD00865419
2物価
選択條件：
ブランド
- Sigma-Aldrich Japan
パッケージ
- 10mg
- 50mg
- 生産者Sigma-Aldrich Japan
- 製品番號SML0042
- 製品説明ラザベミド 水和物 ≥97% (HPLC)
- 英語製品説明Lazabemide hydrate ≥97% (HPLC)
- 包裝単位10mg
- 価格￥15900
- 更新しました2024-03-01
- 購入
- 生産者Sigma-Aldrich Japan
- 製品番號SML0042
- 製品説明ラザベミド 水和物 ≥97% (HPLC)
- 英語製品説明Lazabemide hydrate ≥97% (HPLC)
- 包裝単位50mg
- 価格￥45800
- 更新しました2023-06-01
- 購入
| 生産者 | 製品番號 | 製品説明 | 包裝単位 | 価格 | 更新時(shí)間 | 購入 |
|---|---|---|---|---|---|---|
| Sigma-Aldrich Japan | SML0042 | ラザベミド 水和物 ≥97% (HPLC) Lazabemide hydrate ≥97% (HPLC) |
10mg | ￥15900 | 2024-03-01 | 購入 |
| Sigma-Aldrich Japan | SML0042 | ラザベミド 水和物 ≥97% (HPLC) Lazabemide hydrate ≥97% (HPLC) |
50mg | ￥45800 | 2023-06-01 | 購入 |
プロパティ
沸點(diǎn) :397.4±37.0 °C(Predicted)
比重(密度) :1.286±0.06 g/cm3(Predicted)
貯蔵溫度 :room temp
溶解性 :DMSO: ≥22mg/mL
酸解離定數(shù)(Pka) :12.90±0.46(Predicted)
外見 :powder
色 :white to tan
InChI :1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
InChIKey :JYWYNPKXSLPWGV-UHFFFAOYSA-N
SMILES :O.NCCNC(=O)c1ccc(Cl)cn1
比重(密度) :1.286±0.06 g/cm3(Predicted)
貯蔵溫度 :room temp
溶解性 :DMSO: ≥22mg/mL
酸解離定數(shù)(Pka) :12.90±0.46(Predicted)
外見 :powder
色 :white to tan
InChI :1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
InChIKey :JYWYNPKXSLPWGV-UHFFFAOYSA-N
SMILES :O.NCCNC(=O)c1ccc(Cl)cn1
安全情報(bào)
| 絵表示(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Warning | |||||||||||||||||||||
| 危険有害性情報(bào): |
|
|||||||||||||||||||||
| 注意書き: |
|
説明
Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson’s disease. Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively. It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme. The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitro and ex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson’s disease.関連商品価格
- レナリドミド
￥8700-115200 - テトラメトリン
￥9800-17000 - 5-クロロ-2-ピリジンカルボキシアルデヒド
￥5200-290000